NIM
NEOS Investment Management Portfolio holdings
AUM
$8.08B
This Quarter Return
+4.83%
1 Year Return
+24.46%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.25B
AUM Growth
+$4.25B
(+28%)
Cap. Flow
+$886M
Cap. Flow
% of AUM
20.88%
Top 10 Holdings %
Top 10 Hldgs %
37.69%
Holding
613
New
34
Increased
490
Reduced
55
Closed
25
Top Buys
| 1 |
Vanguard Russell 2000 ETF
VTWO
|
$76.3M |
| 2 |
Apple
AAPL
|
$70.6M |
| 3 |
NVIDIA
NVDA
|
$54.5M |
| 4 |
Microsoft
MSFT
|
$53.4M |
| 5 |
Amazon
AMZN
|
$39.8M |
Top Sells
| 1 |
SPDR Bloomberg Short Term High Yield Bond ETF
SJNK
|
$17.1M |
| 2 |
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
|
$17.1M |
| 3 |
SUM
Summit Materials, Inc. Class A Common Stock
SUM
|
$3.06M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$2.53M |
| 5 |
Insulet
PODD
|
$1.32M |
Sector Composition
| 1 | Technology | 33.68% |
| 2 | Consumer Discretionary | 10.52% |
| 3 | Healthcare | 10.01% |
| 4 | Communication Services | 9.79% |
| 5 | Financials | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
601
Edgewise Therapeutics
EWTX
$1.51B
| – | – | -23,359 | Closed | -$623K |
|
602
Jasper Therapeutics
JSPR
$45.5M
| – | – | -11,219 | Closed | -$211K |
|
603
Oscar Health
OSCR
$4.31B
| – | – | -43,854 | Closed | -$930K |
|
604
Pool Corp
POOL
$11.6B
| – | – | -537 | Closed | -$202K |
|
605
Ferrari
RACE
$85B
| – | – | -469 | Closed | -$220K |
|
|
606
Ultragenyx Pharmaceutical
RARE
$2.89B
| – | – | -45,599 | Closed | -$2.53M |
|
|
607
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
$7.28B
| – | – | -395,438 | Closed | -$17.1M |
|
|
608
SPDR Bloomberg Short Term High Yield Bond ETF
SJNK
$4.88B
| – | – | -668,356 | Closed | -$17.1M |
|
|
SLN
609
Silence Therapeutics
SLN
$227M
| – | – | -51,712 | Closed | -$940K |
|
610
Soleno Therapeutics
SLNO
$3.6B
| – | – | -14,033 | Closed | -$709K |
|
611
Tenaya Therapeutics
TNYA
$184M
| – | – | -169,127 | Closed | -$326K |
|
|
VERV
612
DELISTED
Verve Therapeutics
VERV
| – | – | -95,029 | Closed | -$460K |
|
613
Skye Bioscience
SKYE
$108M
| – | – | -54,871 | Closed | -$215K |
|